復(fù)方血栓通膠囊聯(lián)合胞二磷膽堿治療青光眼視神經(jīng)萎縮的臨床效果

余江平 張學(xué)敏

[摘要] 目的 探討青光眼視神經(jīng)萎縮患者應(yīng)用復(fù)方血栓通膠囊與胞二磷膽堿聯(lián)合治療的臨床效果。方法 方便選擇該院2015年3月—2018年3月收治的青光眼視神經(jīng)萎縮患者作為研究對象，共計納入90例，入組對象簽署知情同意書愿意配合研究，按照隨機數(shù)表法分為單用組與聯(lián)合組，每組45例。其中單用組患者予以胞二磷膽堿治療，聯(lián)合組則采取復(fù)方血栓通膠囊與胞二磷膽堿聯(lián)合治療。評價兩組患者視力效果、視野效果，測定治療前與治療后視力、總灰度值、視野光敏度、視野缺損度情況。結(jié)果 聯(lián)合組患者視力總有效率、視野總有效率依次為93.33%、88.89%，單用組則分別為80.00%、75.56%，聯(lián)合組前述總有效率均高于單用組（P<0.05）；兩組患者治療前視力、總灰度值、視野光敏度、視野缺損度比較差異無統(tǒng)計學(xué)意義（P>0.05），治療后聯(lián)合組前述指標(biāo)均優(yōu)于單用組（P<0.05）。結(jié)論 青光眼視神經(jīng)萎縮患者采取復(fù)方血栓通膠囊與胞二磷膽堿聯(lián)合治療可以更好地改善視力效果與視野效果，同時在改善視力、總灰度值、視野光敏度、視野缺損度等方面也有不錯的優(yōu)勢，值得推廣應(yīng)用。

[關(guān)鍵詞] 青光眼；視神經(jīng)萎縮；復(fù)方血栓通膠囊；胞二磷膽堿；效果

[中圖分類號] R5 [文獻(xiàn)標(biāo)識碼] A [文章編號] 1674-0742（2019）03（b）-0146-03

[Abstract] Objective To investigate the clinical effect of combined treatment of compound Xueshuantong capsule and citicoline in patients with glaucoma optic atrophy. Methods Patients with glaucomatous optic atrophy admitted to our hospital from March 2015 to March 2018 were convenient selected and enrolled in this study. A total of 90 patients were enrolled. The enrolled subjects signed an informed consent form and were willing to cooperate with the study. They were divided into single use group and the combined group， n=45 cases per group according to the random number table method. The patients in the single-use group were treated with citicoline， and the combined group was treated with compound Xueshuantong capsule and citicoline. The visual acuity and visual field effect of the two groups were evaluated. The visual acuity， total gray value， visual field sensitivity and visual field defect degree before and after treatment were measured. Results The total effective rate and total visual acuity of the combined group were 93.33% and 88.89%， respectively， and the single use group was 80.00% and 75.56% respectively. The total effective rate of the combined group was higher than that of the single use group （P<0.05）. There was no significant difference in pre-treatment visual acuity， total gray value， visual field sensitivity， and visual field defect between the two groups （P>0.05）. The above-mentioned indicators in the combined group were better than the single-use group （P<0.05）. Conclusion The combination of compound Xueshuantong Capsule and citicoline in glaucoma optic atrophy can improve the visual effect and visual field effect， and also improve the visual acuity， total gray value， visual field sensitivity， and visual field defect， it is worth promoting.

[Key words] Glaucoma； Optic atrophy； Compound thrombosis capsule； Citicoline； Effect

青光眼屬于常見眼科疾病，指的是眼壓升高或者低灌注壓等所致視神經(jīng)損害性疾病，而且多伴有視神經(jīng)萎縮，常表現(xiàn)出慢性視力與視野損害等癥狀。過去對青光眼視神經(jīng)萎縮治療主要采取營養(yǎng)神經(jīng)性藥物、活血通脈藥物等治療，但這些治療方案預(yù)后并不理想[1]。為了尋找更為有效、安全的治療方案，近幾年通過不斷研究與探索，一些學(xué)者指出復(fù)方血栓通膠囊與胞二磷膽堿聯(lián)合治療青光眼視神經(jīng)萎縮可取得不錯的效果[2-3]，其中胞二磷膽堿屬于核苷衍生物，不僅可參與神經(jīng)組織磷脂與蛋白質(zhì)合成，促進(jìn)這種合成，而且還可調(diào)節(jié)血管張力，使得神經(jīng)組織代謝得到改善[4-5]。為了進(jìn)一步探討青光眼視神經(jīng)萎縮患者應(yīng)用復(fù)方血栓通膠囊與胞二磷膽堿聯(lián)合治療的臨床效果，分析該院2015年3月—2018年3月間收治的90例青光眼視神經(jīng)萎縮患者的臨床資料，報道如下。